Enhancement of Chemotherapy Efficacy in Cervical Cancer via MAPK Pathway Inhibition by Osimertinib.
Cancer Invest
; 42(5): 425-434, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38818695
ABSTRACT
Addressing recurrent cervical cancer poses a substantial challenge. Osimertinib, an FDA-approved EGFR inhibitor, has emerged as a promising option. Our study examined its potential to enhance paclitaxel's efficacy against cervical cancer. Osimertinib effectively hindered cancer cell growth and induced apoptosis across multiple cell lines. Combined with paclitaxel, it exhibited synergy in suppressing cervical cancer cells. Importantly, osimertinib's inhibitory effect was EGFR-independent; it targeted Mnk phosphorylation, reducing eIF4E activity. In mice, the combined osimertinib-paclitaxel treatment surpassed individual drugs in inhibiting cancer growth. These preclinical findings suggest osimertinib's repurposing as a means to improve paclitaxel's effectiveness in cervical cancer treatment.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Acrilamidas
/
Neoplasias del Cuello Uterino
/
Paclitaxel
/
Compuestos de Anilina
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Cancer Invest
Año:
2024
Tipo del documento:
Article
País de afiliación:
China